IN8bio, Inc. (INAB)
INAB Stock Price Chart
Explore IN8bio, Inc. interactive price chart. Choose custom timeframes to analyze INAB price movements and trends.
INAB Company Profile
Discover essential business fundamentals and corporate details for IN8bio, Inc. (INAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jul 2021
Employees
18.00
Website
https://in8bio.comCEO
Tai-Wei Ho
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
INAB Financial Timeline
Browse a chronological timeline of IN8bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.20.
Earnings released on 7 Aug 2025
EPS came in at -$1.24 surpassing the estimated -$1.50 by +17.33%.
Stock split effective on 6 Jun 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2025
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 13 Mar 2025
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%.
Earnings released on 12 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%.
Earnings released on 8 Aug 2024
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%.
Earnings released on 9 May 2024
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%.
Earnings released on 14 Mar 2024
EPS came in at -$0.21 falling short of the estimated -$0.16 by -31.25%, while revenue for the quarter reached $3.75M .
Earnings released on 9 Nov 2023
EPS came in at -$0.23 surpassing the estimated -$0.25 by +8.00%.
Earnings released on 10 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.28 by +3.57%.
Earnings released on 12 May 2023
EPS came in at -$0.30 surpassing the estimated -$0.33 by +9.09%.
Earnings released on 30 Mar 2023
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 10 Nov 2022
EPS came in at -$0.34 falling short of the estimated -$0.28 by -21.43%.
Earnings released on 12 Aug 2022
EPS came in at -$0.38 falling short of the estimated -$0.33 by -15.15%.
Earnings released on 12 May 2022
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%.
Earnings released on 17 Mar 2022
EPS came in at -$0.21 matching the estimated -$0.21.
Earnings released on 10 Nov 2021
EPS came in at -$0.25 surpassing the estimated -$0.33 by +24.24%.
Earnings released on 10 Sept 2021
EPS came in at -$0.16 surpassing the estimated -$0.30 by +45.79%.
Earnings released on 30 Jul 2021
EPS came in at -$0.16 .
Earnings released on 31 Dec 2020
EPS came in at -$0.12 .
Earnings released on 30 Sept 2020
EPS came in at -$0.09 .
INAB Stock Performance
Access detailed INAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.